Exercise Training, Insulin Resistance and Coronary Artery Disease

This study has been completed.

Sponsors and Collaborators:	Lawson Health Research Institute Hamilton Health Sciences Canadian Diabetes Association
Information provided by:	Lawson Health Research Institute
ClinicalTrials.gov Identifier:	NCT00412815

Purpose

The purpose of this study was to determine the effects of exercise training on insulin resistance in subjects with coronary artery disease independent of changes in weight, diet, or the effect of an acute bout of exercise. We hypothesized that subjects with CAD and high normal or impaired glucose tolerance performing 12 weeks of aerobic exercise training while on a non weight-reducing diet, would have a greater decrease in insulin resistance than controls measured at 72 hours following their last bout of exercise.

Condition	Intervention	Phase
Coronary Artery Disease Glucose Intolerance	Behavioral: Exercise training	Phase III

MedlinePlus related topics: Coronary Artery Disease Exercise and Physical Fitness

Drug Information available for: Insulin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Educational/Counseling/Training, Randomized, Single Blind, Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title:	The Effects of Exercise Training on Insulin Resistance in Patients With Coronary Artery Disease and Insulin Resistance, the Exercise, Coronary Artery Disease and Insulin Resistance (EXCADIR) Randomized Controlled Trial

Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:

Insulin sensitivity

Secondary Outcome Measures:

Exercise capacity

Estimated Enrollment:	60
Study Start Date:	July 1997
Estimated Study Completion Date:	January 2001

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

men and women over 18 years of age
fasting plasma glucose concentration 5.4-7.7 mmol/L
confirmed CAD (diagnosed on the basis of a previous myocardial perfusion study or cardiac catheterization, or a history of a myocardial infarction or coronary artery angioplasty or coronary artery bypass surgery).

Exclusion Criteria:

known type 1 or 2 diabetes
clinical heart failure
uncorrected significant valvular or congenital heart disease
significant obstructive pulmonary disease (forced expiratory volume in 1 sec / forced vital capacity < 0.5)
uncontrolled hypertension (blood pressure > 220 / 120 mm Hg)
participation in a regular exercise program within the preceding three months
inability to perform exercise training, atrial fibrillation
a permanent pacemaker
regularly used corticosteroid
recent (< 3 months) myocardial infarction, unstable angina, coronary artery bypass graft surgery, or coronary artery angioplasty
run-in phase fasting blood glucose was < 5.4 mmol/L or > 11.1 mmol/L at 2 hours following the 75 gram oral glucose load.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00412815

Locations

Canada, Ontario
Hamilton Health Sciences Centre
Hamilton, Ontario, Canada, L8L2X2

Sponsors and Collaborators

Lawson Health Research Institute

Hamilton Health Sciences

Canadian Diabetes Association

Investigators

Principal Investigator:

Robert S McKelvie, MD

McMaster Univesrity

More Information

Study ID Numbers:	R-99-004
Study First Received:	December 14, 2006
Last Updated:	December 14, 2006
ClinicalTrials.gov Identifier:	NCT00412815
Health Authority:	Canada: Ethics Review Committee

Keywords provided by Lawson Health Research Institute:

insulin sensitivity
coronary artery disease
exercise training

Study placed in the following topic categories:

Arterial Occlusive Diseases
Heart Diseases
Metabolic Diseases
Myocardial Ischemia
Glucose Intolerance
Vascular Diseases
Ischemia
Arteriosclerosis

Insulin
Coronary Disease
Hyperinsulinism
Hyperglycemia
Insulin Resistance
Metabolic disorder
Glucose Metabolism Disorders
Coronary Artery Disease

Additional relevant MeSH terms:

Hypoglycemic Agents
Physiological Effects of Drugs
Cardiovascular Diseases
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009